Endoplasmic Stress Inhibitors for Homocysteine Induced Cardiovascular Disease

Curr Pharm Des. 2016;22(18):2704-8. doi: 10.2174/1381612822666160406121342.

Abstract

Cardiovascular disease (CVD) remains a major cause of death and disability worldwide, thus preventing and inhibiting CVD remains a health priority. Several lines of pharmacological interventions have not met with great success, thus inhibition of novel cellular stress pathways could be a novel therapeutic avenue to treat CVD. This review will focus on homocysteine and endoplasmic reticulum stress linked to mitochondria function, and possible therapeutic avenues for treatment.

Publication types

  • Review

MeSH terms

  • Animals
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / metabolism
  • Endoplasmic Reticulum / drug effects*
  • Endoplasmic Reticulum / metabolism
  • Endoplasmic Reticulum Stress / drug effects*
  • Homocysteine / antagonists & inhibitors*
  • Homocysteine / metabolism
  • Humans
  • Mitochondria / drug effects
  • Mitochondria / metabolism

Substances

  • Homocysteine